DexTech Medical AB

DexTech Medical operates in biotechnology. The company conducts research and development in the field of urological oncology, where common diseases include prostate cancer. A large part of the research is carried out in collaboration with other international players, research institutes and universities. The largest operations are found in the Nordic market. The company was founded in 2004 and is headquartered in Uppsala.

Quotes for DexTech Medical AB

Board

CEO

  • Anders Holmberg

Chairperson of the Board

  • Andreas Segerros

Board

  • Per-Olov Asplund
  • Peter Benson
  • Rolf Eriksson
  • Svante Wadman
Articles of association

Videos

1 / 1
Hearing med DexTech
HappeningEvent Hearing med DexTech
** Powered by Modular Finance
*Powered by Modular Finance
Key Numbers
2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-06-30 2025-03-31 2024-12-31
Number of months that the report spans Q3 3 Months Q2 3 Months Q1 3 Months 2025 Q4 3 Months Q3 3 Months Q2 3 Months
Total revenue MSEK 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings before interest and tax MSEK -1.75 -1.68 -1.34 -5.32 -1.57 -1.34 -1.11
Profit before tax MSEK -1.73 -1.63 -1.26 -4.85 -1.50 -1.24 -0.96
Net profit MSEK -1.73 -1.63 -1.26 -4.85 -1.50 -1.24 -0.96
Earnings per share SEK -0.09 -0.09 -0.07 -0.26 -0.08 -0.07 -0.05
Dividend per share SEK 0,00 0,00 0,00 0.00 0,00 0,00 0,00
Equity MSEK 20.14 21.88 24.76 24.76 24.76 26.26 27.51
Fixed assets MSEK 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Intangible assets MSEK 9.88 9.64 9.68 9.92 9.92 10.47 11.03
Current assets MSEK 10.80 12.68 14.57 15.18 15.18 16.08 16.69
Total asset MSEK 20.68 22.32 24.25 25.10 25.10 26.55 27.72
Long term liabilities MSEK 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Current liabilities MSEK 0.54 0.44 0.75 0.34 0.34 0.29 0.21
Number of shares SEK 18485857.00 18485857.00 18485857.00 18485857.00 18485857.00 18485857.00 18485857.00
*Compiled data from Millistream